Sign up to save your podcasts
Or
Share Hot Bytes: Ozempic, Weight Loss, Big Tech, and the End of Impulse
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Hot Bytes: Ozempic, Weight Loss, Big Tech, and the End of Impulse
Driving Question:
How do GLP-1 drugs disrupt Big Tech, digital advertising, and consumer behavior when impulse and desire start to decline?
Episode Description:
GLP-1 drugs like Ozempic and Wegovy are changing more than weight loss they’re reshaping consumer behavior, digital advertising, and Big Tech’s attention economy.
In this Hot Bytes episode of culturally/INCOMPETENT, we break down how GLP-1 medications are reducing impulse consumption and why that matters for platforms like Meta and TikTok, industries built on advertising, and brands that rely on predictable desire. As appetite and cravings decline, fast food, alcohol, retail, and AdTech face a structural shift that challenges the economics of endless consumption.
Using recent economic research and analysis of social media advertising, this episode explores the intersection of healthcare technology, algorithms, capitalism, and culture and asks what happens when biology begins to interfere with platforms designed to monetize impulse.
View all episodes
By Nicholas LindseyDriving Question:
How do GLP-1 drugs disrupt Big Tech, digital advertising, and consumer behavior when impulse and desire start to decline?
Episode Description:
GLP-1 drugs like Ozempic and Wegovy are changing more than weight loss they’re reshaping consumer behavior, digital advertising, and Big Tech’s attention economy.
In this Hot Bytes episode of culturally/INCOMPETENT, we break down how GLP-1 medications are reducing impulse consumption and why that matters for platforms like Meta and TikTok, industries built on advertising, and brands that rely on predictable desire. As appetite and cravings decline, fast food, alcohol, retail, and AdTech face a structural shift that challenges the economics of endless consumption.
Using recent economic research and analysis of social media advertising, this episode explores the intersection of healthcare technology, algorithms, capitalism, and culture and asks what happens when biology begins to interfere with platforms designed to monetize impulse.